GlassScriptPhysician profile
Tinofa Muskwe
NPI 1902861156
$2,029.96
in general payments reported to CMS, 2019-2025
12 companies · $348 in 2025
The $348 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.45 · 2022: $221 · 2023: $927 · 2024: $519 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,510 · Travel and Lodging: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.04 |
| Travel and Lodging | $283.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $378.44 | 2023-2025 | Nucala, Arexvy |
| Intuitive Surgical, INC. | $374.05 | 2023-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $253.26 | 2020-2024 | Imfinzi, Tezspire |
| Regeneron Healthcare Solutions, INC. | $223.23 | 2024 | Dupixent |
| Merck Sharp & Dohme LLC | $123.43 | 2022 | |
| Amgen INC. | $115.17 | 2024 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.80 | 2025 | |
| Abbvie INC. | $113.26 | 2023 | |
| Genzyme Corporation | $110.31 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.74 | 2023-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $97.33 | 2022 | |
| Viatris Specialty LLC | $16.94 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tinofa Muskwe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.